LL-37
LL-37 (Cathelicidin Antimicrobial Peptide)
Your body's own antimicrobial weapon — a natural peptide that kills bacteria, viruses, and fungi while helping wounds heal faster.
LL-37 is the only cathelicidin antimicrobial peptide that the human body produces on its own. It is made up of 37 amino acids, and its name comes from the fact that it starts with two leucine amino acids (LL) and is 37 amino acids long. Think of it as one of your immune system's built-in weapons against bacteria, viruses, fungi, and parasites.
Your body creates LL-37 from a larger precursor protein called hCAP-18. When your immune system detects a threat — an infection, a wound, a foreign invader — enzymes cut this precursor protein to release the active LL-37 peptide. This happens inside immune cells like neutrophils, macrophages, dendritic cells, and natural killer cells, as well as in the cells that line your skin, lungs, and digestive tract.
What makes LL-37 stand out from traditional antibiotics is its versatility. Rather than targeting just one weakness in a pathogen the way most antibiotics do, LL-37 attacks through multiple pathways at once. It can kill pathogens directly, regulate the immune response, neutralize dangerous bacterial toxins, promote wound healing, and even stimulate the growth of new blood vessels. Because it uses so many different strategies simultaneously, it is very difficult for bacteria to develop resistance against it.
LL-37 has attracted significant scientific attention as antibiotic resistance becomes one of the most serious threats to global health. The World Health Organization has identified antimicrobial resistance as a top-ten global health threat. LL-37 represents a fundamentally different approach to fighting infection because it works alongside your immune system rather than simply poisoning bacteria the way traditional antibiotics do. Clinical trials have already tested topical LL-37 for wound healing in venous leg ulcers with promising results.
How It Works
LL-37 kills pathogens primarily by destroying their outer protective layer, called the cell membrane. The peptide has a special two-sided structure: one side is attracted to water and the other side is attracted to fat. This unique shape allows it to insert itself directly into the fatty membranes that surround bacteria and punch holes in them.
The process works because bacterial membranes carry a negative electrical charge, while human cell membranes are neutral. LL-37 is naturally attracted to that negative charge, so it homes in on bacteria while leaving your own cells alone. Once it reaches a bacterial membrane, it inserts its fat-loving side into the membrane. Multiple LL-37 molecules then group together and form channels or pores. The membrane loses its integrity, the contents of the bacterium leak out, and the pathogen dies. Because bacteria cannot easily change this fundamental feature of their membranes without killing themselves, it is very difficult for them to develop resistance to LL-37.
Beyond directly killing pathogens, LL-37 has powerful effects on how your immune system responds to threats. It neutralizes lipopolysaccharide (LPS), a dangerous bacterial toxin that can trigger septic shock. It sends out chemical signals that recruit immune cells to the site of infection. It keeps immune cells called neutrophils alive longer during active infections so they can continue fighting. It stimulates the growth of new blood vessels to support wound healing and promotes skin cell migration to close wounds. It also helps balance the inflammatory response so your immune system fights effectively without going overboard.
LL-37 also has the ability to break through biofilms. Biofilms are communities of bacteria that encase themselves in a protective slimy matrix, making them extremely resistant to antibiotics — often 100 to 1,000 times more resistant than free-floating bacteria. LL-37 can penetrate and disrupt these biofilm structures, exposing the bacteria inside to clearance by your immune system.
Potential Benefits
Broad-Spectrum Antimicrobial Activity
LL-37 is effective against a remarkably wide range of pathogens including gram-positive bacteria like Staphylococcus and Streptococcus, gram-negative bacteria like E. coli, Pseudomonas, and Klebsiella, fungi, and enveloped viruses. This broad activity makes it particularly valuable when the specific pathogen causing an infection is unknown or when multiple types of pathogens are involved at the same time.
Biofilm Disruption
Chronic infections often involve biofilms — communities of bacteria encased in a protective matrix that makes them 100 to 1,000 times more resistant to antibiotics than free-floating bacteria. LL-37 can penetrate and break apart these biofilm structures, exposing the bacteria to clearance by the immune system. This has important implications for conditions like chronic sinusitis, chronic wound infections, and infections associated with medical devices.
Wound Healing
Clinical trials in venous leg ulcers demonstrated that topical LL-37 accelerated wound closure. The peptide promotes the regrowth of skin by stimulating the migration of skin cells called keratinocytes, enhances the formation of new blood vessels to improve blood supply to the wound, and provides antimicrobial protection against wound infection — all at the same time.
Immune Modulation
Rather than simply turning the immune system up or down, LL-37 helps regulate immune responses in a balanced way. It enhances the clearance of pathogens while simultaneously neutralizing bacterial toxins that could trigger excessive, harmful inflammation. This balanced approach makes it valuable for managing chronic inflammatory conditions where the immune system needs to be effective without being overactive.
Synergy with Antibiotics
Studies show LL-37 works synergistically with various antibiotics including beta-lactams and vancomycin. By disrupting bacterial membranes first, LL-37 allows antibiotics better access to their targets inside the bacterial cell. This combination approach can help overcome antibiotic resistance in some cases, making previously ineffective antibiotics useful again.
Endotoxin Neutralization
LL-37 binds and neutralizes lipopolysaccharide (LPS), the bacterial endotoxin that is responsible for triggering septic shock — a life-threatening condition. This protective effect against endotoxemia has been demonstrated in animal models and represents an important safety mechanism during bacterial infections.
What the Research Shows
A randomized controlled trial by Gronberg and colleagues in 2014 tested topical LL-37 on patients with hard-to-heal venous leg ulcers. Thirty-four patients were randomly assigned to receive either a vehicle (inactive base), a lower concentration of LL-37 at 0.5 mg/mL, or a higher concentration at 1.6 mg/mL. Treatment was applied twice weekly for three weeks. Both LL-37 groups showed significantly improved wound healing compared to the vehicle group. The lower concentration group actually had the best results with fewer side effects, and no serious adverse events were linked to the peptide.
Extensive laboratory research has demonstrated that LL-37 is effective against a wide range of dangerous pathogens. These include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus, Pseudomonas aeruginosa biofilms, Candida fungal species, herpes simplex virus, and influenza virus. Studies also show LL-37 works synergistically with various antibiotics including beta-lactams and vancomycin — the peptide disrupts bacterial membranes, allowing antibiotics better access to their intracellular targets, which can help overcome resistance.
Research has established an important connection between vitamin D and LL-37. Vitamin D is a key regulator of cathelicidin expression, which means your vitamin D levels directly influence how much LL-37 your body produces naturally. This discovery helps explain why people with vitamin D deficiency tend to get sick more often. Studies show that maintaining optimal vitamin D levels (40 to 60 ng/mL) supports your body's natural LL-37 production.
Several challenges have been identified in the research. LL-37 can be inactivated by serum proteins in the blood, which reduces its effectiveness when used systemically. At high concentrations, it can become toxic to the body's own cells. The peptide is susceptible to being broken down by enzymes in the body, and it is expensive to synthesize because of its length at 37 amino acids. These limitations have driven ongoing research into modified versions of LL-37 with improved stability and reduced toxicity.
What to Know
Injection site reactions are the most frequently reported side effects, including redness, swelling, burning or stinging sensation during injection, and mild itching. These reactions are caused by LL-37's local immune-stimulating effects and typically resolve within a few hours.
Some users report flu-like symptoms during the first few days of use, including low-grade fever, fatigue, body aches, and general malaise. This is thought to result from cytokine release as LL-37 activates immune cells, and typically diminishes as the body adjusts.
LL-37 is elevated in certain autoimmune and inflammatory conditions including psoriasis, rosacea, and lupus. Supplementation may theoretically worsen these conditions. People with rosacea should avoid LL-37 because it is already overexpressed in rosacea lesions.
The peptide may aggravate inflammatory bowel conditions in some individuals. People with inflammatory bowel disease should monitor carefully for changes in symptoms.
At high concentrations, LL-37 can become cytotoxic, meaning it can damage the body's own cells. This is why protocols stay well below the known toxicity threshold. Long-term effects of chronic supplementation are unknown.
Should be avoided by pregnant or breastfeeding women due to insufficient safety data, and by anyone with known hypersensitivity to the peptide. People on immunosuppressive medications should use with care under medical guidance.
Research References
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Durr UH, Sudheendra US, Ramamoorthy A · Biochimica et Biophysica Acta · 2006
Comprehensive review establishing LL-37 as the sole human cathelicidin antimicrobial peptide, covering its structure, mechanism of action, and broad-spectrum antimicrobial activity against bacteria, viruses, and fungi.
View StudyTreatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial
Gronberg A, Mahlapuu M, Stahle M, Whately-Smith C, Heilborn JD · Wound Repair and Regeneration · 2014
Randomized controlled trial of 34 patients showing that topical LL-37 at 0.5 mg/mL significantly improved healing of chronic venous leg ulcers compared to vehicle, with no serious adverse events attributed to the peptide.
View StudyNatural and synthetic cathelicidin peptides with antimicrobial and antibiofilm activity against Staphylococcus aureus
Dean SN, Bishop BM, van Hoek ML · BMC Microbiology · 2011
Demonstrated that both natural LL-37 and synthetic cathelicidin peptide variants exhibit potent antimicrobial and antibiofilm activity against Staphylococcus aureus, including drug-resistant strains.
View StudyHuman host defense peptide LL-37 prevents bacterial biofilm formation
Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE · Infection and Immunity · 2008
Showed that LL-37 prevents bacterial biofilm formation by Pseudomonas aeruginosa at concentrations below those needed to kill bacteria, revealing an important anti-biofilm mechanism independent of direct killing.
View StudyHost defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections
Nijnik A, Hancock RE · Emerging Health Threats Journal · 2009
Review of host defense peptides including LL-37, covering their dual antimicrobial and immunomodulatory activities and their potential as a new class of therapeutics against antibiotic-resistant infections.
View StudyThe Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard KE, Overhage J · Antibiotics (Basel) · 2021
Up-to-date review examining LL-37's potential as both an antimicrobial and anti-biofilm agent, covering recent advances in understanding its mechanisms and efforts to develop it for clinical use.
View Study